首页> 外文期刊>Journal of the European Academy of Dermatology and Venereology: JEADV >Protocol for the development of core set of domains of the core outcome set for patients with congenital melanocytic naevi (OCOMEN project)
【24h】

Protocol for the development of core set of domains of the core outcome set for patients with congenital melanocytic naevi (OCOMEN project)

机译:先天性黑素细胞Naevi(Ocomen项目)核心成果核心结果核心域核心组核心组的议定书

获取原文
获取原文并翻译 | 示例
           

摘要

Abstract Background Having large congenital melanocytic naevi (CMN) is associated with a psychosocial burden on patients and their parents because of its remarkable appearance and the extra care it may require. Large CMN also pose an increased risk of malignant melanoma or neurocutaneous melanosis. There is a lack of international consensus on what important outcome domains to measure in relation to treatment. This makes it difficult to compare options, to properly inform patients and their parents, and to set up treatment policy for CMN. Therefore, we aim to develop a core outcome set (COS), i.e. the minimum set of outcomes that are recommended to be measured and reported in all clinical trials of a specific health condition. This COS can be used in the follow‐up of CMN patients with or without treatment, in clinical research and practice. Methods In the Outcomes for Congenital Melanocytic Nevi (OCOMEN) projects, we follow the recommendations from the Core Outcome Measures in Effectiveness Trials (COMET) initiative and the Cochrane Skin Core Outcomes Set Initiative (CS‐COUSIN). This project entails the following: (i) a systematic review to identify the previous reported outcomes in literature; (ii) focus groups with national and international patients and parents to identify patient‐important outcomes; (iii) classification of outcomes into outcome domains; (iv) e‐Delphi surveys in which stakeholders (patients/parents and professionals) can rate the importance of domains and outcomes; and (v) an online consensus meeting to finalize the core outcome domains of the COS. Results The results will be disseminated by means of publication in a leading journal and presentations in international meetings or conferences. We engage international experts in CMN, both patients and professionals, to ensure the international utility and applicability of the COS.
机译:摘要背景有大型先天性黑素细胞Naevi(CMN)与患者和父母的心理社会负担有关,因为它可能需要的卓越外观和额外的护理。大型CMN也造成了恶性黑素瘤或神经皮肤病的风险增加。缺乏关于衡量治疗的重要成果领域的国际共识。这使得难以比较选项,正确地通知患者及其父母,并为CMN建立治疗政策。因此,我们的目标是开发核心结果组(COS),即在特定健康状况的所有临床试验中衡量和报告的最小结果。在临床研究和实践中,该COS可用于CMN患者的随访或无需治疗。方法在先天性素细胞痣(OCOMEN)项目的结果中,我们遵循有效试验(COMET)倡议的核心结果措施的建议和Cochrane皮肤核心结果设定倡议(CS-Cousin)。该项目需要以下内容:(i)系统审查,以确定先前的文学报告的结果; (ii)与国家和国际患者和父母的焦点小组识别患者重要的结果; (iii)成果域的成果分类; (iv)e-delphi调查,其中利益相关者(患者/父母和专业人士)可以评估域名和结果的重要性; (v)在线共识会议,以最终确定COS的核心成果领域。结果,结果将通过在国际会议或会议中的领先期刊和介绍中发布来传播结果。我们从事CMN,患者和专业人士的国际专家,以确保COS的国际实用性和适用性。

著录项

  • 来源
  • 作者单位

    Department of DermatologyUniversity Medical Center RotterdamRotterdam The?Netherlands;

    Department of Plastic Reconstructive and Hand SurgeryAmsterdam University Medical CenterAmsterdam;

    Department of Public HealthUniversity Medical Center RotterdamRotterdam The Netherlands;

    Department of DermatologyUniversity Medical Center RotterdamRotterdam The?Netherlands;

    Department of Plastic Reconstructive and Hand SurgeryAmsterdam University Medical CenterAmsterdam;

    Department of DermatologyAmsterdam University Medical CenterAmsterdam The Netherlands;

    Department of Plastic Reconstructive and Hand SurgeryAmsterdam University Medical CenterAmsterdam;

    Department of DermatologyAmsterdam University Medical CenterAmsterdam The Netherlands;

    Leader of Patient Representatives of Naevus InternationalUtrecht The Netherlands;

    Department of DermatologyUniversity Medical Center RotterdamRotterdam The?Netherlands;

  • 收录信息
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类 皮肤病学与性病学;
  • 关键词

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号